Literature DB >> 15309708

Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro.

Da-Qiang Li1, Zhi-Biao Wang, Jin Bai, Jie Zhao, Yuan Wang, Kai Hu, Yong-Hong Du.   

Abstract

AIM: To explore the effects of mifepristone, a progesterone receptor (PR) antagonist, on the proliferation of human gastric adenocarcinoma cell line SGC-7 901 in vitro and the possible mechanisms involved.
METHODS: In situ hybridization was used to detect the expression of PR mRNA in SGC-7901 cells. After treatment with various concentrations of mifepristone (2.5, 5, 10, 20 micromol/L) at various time intervals, the ultrastructural changes, cell proliferation, cell-cycle phase distribution, and the expression of caspase-3 and Bcl-XL were analyzed using transmission electron microscopy (TEM), tetrazolium blue(MTT) assay, 3H-TdR incorporation, flow cytometry, and reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: Mifepristone markedly induced apoptosis and inhibited cell proliferation of PR- positive SGC-7901 cells revealed by TEM, MTT assay and 3H-TdR incorporation, in a dose- and time-dependent manner. The inhibitory rate was increased from 8.98% to 51.29%. Flow cytometric analysis showed mifepristone dose-dependently decreased cells in S and G2/M phases, increased cells in G0/G1 phase, reduced the proliferative index from 57.75% to 22.83%. In addition, mifepristone up-regulated the expression of caspase-3, and down- regulated the Bcl-XL expression, dose-dependently.
CONCLUSION: Mifepristone effectively inhibited the proliferation of PR-positive human gastric adenocarcinoma cell line SGC-7901 in vitro through multiple mechanisms, and may be a beneficial agent against human adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309708      PMCID: PMC4572182          DOI: 10.3748/wjg.v10.i18.2628

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Phase II study of mifepristone (RU486) in refractory ovarian cancer.

Authors:  T F Rocereto; H M Saul; J A Aikins; J Paulson
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

2.  Combined modality treatment for locally advanced gastric cancer.

Authors:  Antonino De Paoli; Angela Buonadonna; Giovanni Boz; Davide Lombardi; Roberto Innocente; Salvatore Tumolo; Giancarlo Tosolini; Carlo Rossi; Mauro G Trovò; Sergio Frustaci
Journal:  Suppl Tumori       Date:  2003 Sep-Oct

3.  Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.

Authors:  M Thomas; J D Monet
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

4.  Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells.

Authors:  M F El Etreby; Y Liang; R W Wrenn; P V Schoenlein
Journal:  Breast Cancer Res Treat       Date:  1998-09       Impact factor: 4.872

5.  Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice.

Authors:  M F El Etreby; Y Liang; M H Johnson; R W Lewis
Journal:  Prostate       Date:  2000-02-01       Impact factor: 4.104

6.  Synergistic effects of danazol and mifepristone on the cytotoxicity of UCN-01 in hormone-responsive breast cancer cells.

Authors:  Y Yokoyama; A Shinohara; Y Takahashi; X Wan; S Takahashi; K Niwa; T Tamaya
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

7.  Inhibition of endometrial cancer cell lines by mifepristone (RU 486).

Authors:  C C Schneider; R K Gibb; D D Taylor; T Wan; C Gerçel-Taylor
Journal:  J Soc Gynecol Investig       Date:  1998 Nov-Dec

Review 8.  Combined treatments in gastric cancer: radiotherapy.

Authors:  Vincenzo Valentini; Francesco Cellini; Rolando M D'Angelillo
Journal:  Suppl Tumori       Date:  2003 Sep-Oct

9.  Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice.

Authors:  M F El Etreby; Y Liang
Journal:  Breast Cancer Res Treat       Date:  1998-05       Impact factor: 4.872

10.  Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor.

Authors:  M E Meyer; A Pornon; J W Ji; M T Bocquel; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  9 in total

1.  Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.

Authors:  Elizabeth M Freeburg; Alicia A Goyeneche; Carlos M Telleria
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

2.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

3.  Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Authors:  Alicia A Goyeneche; Erin E Seidel; Carlos M Telleria
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

Review 4.  The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature.

Authors:  Giulia Cossu; Marc Levivier; Roy Thomas Daniel; Mahmoud Messerer
Journal:  Biomed Res Int       Date:  2015-06-03       Impact factor: 3.411

5.  Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study.

Authors:  Mariana Segovia-Mendoza; Rafael Jurado; Roser Mir; Luis A Medina; Heriberto Prado-Garcia; Patricia Garcia-Lopez
Journal:  BMC Cancer       Date:  2015-01-27       Impact factor: 4.430

Review 6.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

7.  Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin.

Authors:  Heather E Kapperman; Alicia A Goyeneche; Carlos M Telleria
Journal:  Cancer Cell Int       Date:  2018-11-15       Impact factor: 5.722

8.  A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro.

Authors:  Qi-Long Sun; Xu-Guang Zhang; Quan-Tai Xing; Peng Ding; Jin-Bo Feng; Xiao-Peng Wu; Zhan-Min Wang
Journal:  Onco Targets Ther       Date:  2012-11-09       Impact factor: 4.147

Review 9.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.